Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. Issue 5 (23rd April 2018)

• Record Type: Journal Article
• Authors: Van de Vondel, Saartje; Baert, Filip; Reenaers, Christine; Vanden Branden, Stijn; Amininejad, Leila; Dewint, Pieter; Van Moerkercke, Wouter; Rahier, Jean-François; Hindryckx, Pieter; Bossuyt, Peter; Ferrante, Marc; Baert, F; De Wulf, D; Moortgat, L; De Cock, E; Decaestecker, L; D'Hondt, A; Van Moerkercke, W; Himpe, S; Dewint, P; Reenaers, C; Van Kemzeke, C; Louis, E; Rahier, J F; Amininejad, L; Franchimont, D; Wambacq, V; Bossuyt, P; Van de Schoot, I; Asnong, K; Vanden Branden, S; Sterckx, A; Hindryckx, P; De Vos, M; Ferrante, M; Noman, M; Vermeire, S; Van Assche, G; Franchimont, D; Rahier, J -F; Ferrante, M; Vermeire, S;
• Is Part Of: Inflammatory bowel diseases. Volume 24:Issue 5(2018)
• Publication Date: 2018-04-23
• Subjects: adalimumab -- ose-optimization -- dose escalation -- dose de-escalation -- ulcerative colitis; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izx103
• Languages: English
• ISSNs: 1078-0998